Dr. Grace Wang, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 387
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: University of Miami, Lm Miller School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME0030904
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Hospital of Miami Miami, FL
- South Miami Hospital Miami, FL
- Doctors Hospital Coral Gables, FL
- Mariners Hospital Tavernier, FL
- Fishermen's Community Hospital Marathon, FL
Medical groups
- Baptist Health Medical Group Oncology LLC (204 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 387
- Services billed
- 948
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 692 | 360 |
| Established patient office or other outpatient visit, 20-29 minutes | 75 | 66 |
| New patient office or other outpatient visit, 60-74 minutes | 42 | 42 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Miami, FL | 173 |
| Letrozole Other prescribers in Miami, FL | 57 |
| Ibandronate Sodium Other prescribers in Miami, FL | 55 |
| Exemestane | 35 |
| Tamoxifen Citrate Other prescribers in Miami, FL | 31 |
| Verzenio (abemaciclib) | 14 |
| Eliquis (apixaban) Other prescribers in Miami, FL | 14 |
| Clotrimazole-Betamethasone (clotrimazole/betamethasone dip) Other prescribers in Miami, FL | 13 |
| Truqap (capivasertib) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $259 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $148 |
|---|---|
| Merck Sharp & Dohme LLC | $41.20 |
| Tempus Ai, Inc | $24.55 |
| Novartis Pharmaceuticals Corporation | $23.08 |
| Daiichi Sankyo Inc. | $21.98 |
| Food and Beverage | $259 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $83,285 in research payments for these studies, mostly to the institutions running them.
- A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
Daiichi Sankyo Inc. · Terminated · NCT03248492 - A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Daiichi Sankyo Inc. · Recruiting · NCT06174987 - DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo Inc. · Completed · NCT03523585 - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997 - Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Br…
Gilead Sciences, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.